Operates a dermatology and skincare clinic chain across India and sells related wellness products. Total net revenue stood at ₹22,248 lakh in FY26, up 2% year on year, while clinic collections reached ₹25,533 lakh. Q4 FY26 clinic revenue grew 7%, led by Acne & Scars treatments up 52%, Haircare up 20% and Brightening & Pigmentation up 28%; the product business grew 21% in the same quarter. Despite this top-line stability, the company posted a net loss of ₹9,617.31 lakh for FY26 — nearly triple the prior year's ₹3,336.77 lakh loss — and shareholders' reserves turned negative at ₹(16,794.97) lakh. The largest cost bucket is 'other operating expenses' at 74.1% of revenue, with employee costs at 31.5% and depreciation at 19.8%. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Clinic services, Product sales. Service-heavy dermatology and wellness chain with persistent losses
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 324 | 377 | 404 | 217 | 222 |
| EBITDA (ex other income) | (2) | (25) | (43) | 18 | (25) |
| margin % | (0.5) | (6.6) | (10.7) | 8.2 | (11.3) |
| Owners' profit | (69) | (116) | (129) | 84 | (96) |
| EPS, as reported (₹) | (52.69) | (89.15) | (98.91) | 63.95 | (66.67) |
| ROE % · ROCE % | 6635.4 · (31.7) | 112.8 · (66.2) | 57.2 · (984.7) | (60.0) · (2.9) | 63.0 · (57.4) |
| Debt / equity (x) | (84.10) | (1.38) | (0.78) | (1.20) | (1.07) |
| Cash from operations | 30 | 63 | 39 | 1 | 21 |
| Capex | (16) | (25) | (36) | (30) | (41) |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 61 | 53 | 58 | 55 | 53 | 54 | 60 | 56 |
| Profit before tax | (6) | (11) | (11) | (11) | (14) | (19) | (36) | (28) |
| Net profit | 103 | (16) | 4 | (7) | (14) | (19) | (36) | (28) |
| EPS (₹) | 78.60 | (11.97) | 2.81 | (5.36) | (10.76) | (13.18) | (23.41) | (18.28) |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| JEENA SIKHO LIFECARE LTD | 6,364 | 26.9 | 13.63 | 17.7 | 47.5 | 52.2 | — | 47.4 |
| KAYA LIMITED ◆ | 506 | — | — | — | 63.0 | (91.1) | (4.1) | (12.4) |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| ROCE | (91.1) | 5.4 | 101 of 101 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 8 Sept 2026 · NSE seeks clarification on missing Q1 FY27 consolidated results | regulatory legal | high | — | — |
| 7 Sept 2026 · EGM results: preferential share issue and key director appointments approved | board shareholder meetings | low | — | — |
| 5 Sept 2026 · EGM proceedings - preferential share issue, leadership change, ESOP amendments | board shareholder meetings | medium | — | — |
| 2 Sept 2026 · Kaya Limited: VP and Head IT resigns, last day November 30 | management changes | medium | — | — |
| 13 Aug 2026 · Newspaper publication of EOGM notice to shareholders | compliance | minimal | — | — |
| 12 Aug 2026 · Kaya EGM Sept 5: Rs 50 Cr preferential issue, MD/Chairman change, ESOP expansion | board shareholder meetings | low | — | — |
| 10 Aug 2026 · Kaya grants 75,000 stock options to staff under ESOP 2021 Scheme VI | capital market events | low | — | — |
| 10 Aug 2026 · Board approves preferential issue of 18.24 lakh equity shares | fund raising | high | — | — |
| 7 Aug 2026 · Vasuta Agarwal re-appointed as Independent Director at Kaya | management changes | medium | — | — |
| 7 Aug 2026 · Vasuta Agarwal re-appointed as Independent Director at Kaya | management changes | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| 0% |
| ROE | 63.0 | 5.8 | 3 of 87 | 98% |
| Debt / Equity | (1.1) | 0.1 | 4 of 87 | 97% |
| EBITDA margin | (12.4) | 23.4 | 78 of 85 | 8% |
| Revenue growth | 2.0 | 12.1 | 64 of 89 | 28% |
| Profit growth | (295.3) | 17.5 | 78 of 83 | 6% |
| Market cap | 506 | 388 | 45 of 103 | 57% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
